N
New View Surgical
Focused on improving the outcomes of laparoscopic surgical procedures
About New View Surgical
New View Surgical, Inc. operates within the minimally invasive surgery (MIS) sector, focusing on the commercialization of advanced visualization technologies. Founded in December 2009 by Art McKinley, Jesse Plouffe, and Bryce Klontz, the Boston-based company aims to enhance the outcomes of laparoscopic surgical procedures. The firm's direction is significantly shaped by the extensive experience of its leadership. Bryce Klontz, the former President and CEO, brought over two decades of medtech experience, including a tenure as Vice President of Commercial Strategy and Emerging Markets at Covidien, where he was instrumental in expanding into new global markets. This background in global commercial strategy is pivotal to New View Surgical's mission.
The company's core offering is the VisionPort™ System, a surgical imaging and access platform. This system consolidates four separate pieces of surgical equipment—the laparoscope, camera, light source, and access port—into a single, disposable device. This integration is designed to streamline surgical workflows by giving the surgeon direct control over visualization, which traditionally requires a dedicated assistant. A key feature of the VisionPort is its dual-camera design, which provides multiple, simultaneous views of the surgical field, a capability not available with conventional laparoscopes. By eliminating the need for a separate camera port, the system can reduce the number of incisions required for a procedure. The first-in-human use of the VisionPort System was for a laparoscopic cholecystectomy (gallbladder removal) in December 2022.
New View Surgical's business model centers on the sale of its disposable VisionPort System to hospitals and surgical centers. The company targets a broad range of diagnostic and therapeutic procedures within the thoracic and abdominal cavities. A significant part of its value proposition is the potential for cost savings for healthcare facilities by reducing the need for capital-intensive equipment and potentially decreasing case times and staffing requirements. The company has successfully navigated the regulatory landscape, receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VisionPort System in June 2021. To finance its operations, development, and commercialization efforts, New View Surgical has raised a total of $26.8 million through several funding rounds, including a $12.1 million Series B round in September 2022, with investments from groups like New York Angels, Mid Atlantic Bio Angels, and Keiretsu Forum.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Boston, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 65.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Medical Imaging, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Oct 2022 | $12M | $48M | Undisclosed | ↗ |
| OtherOther financing | Jun 2022 | $0 | — | MedTech Innovator | ↗ |
Growth signals
Latest recorded traffic for New View Surgical is 1.9K monthly website visits, up 295.8% over the last three months. New View Surgical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
New View Surgical in the Boston ecosystem
The New View Surgical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
MassChallenge
Keiretsu Forum
Series A7 investors entered at this stage
New York Angels
Mid Atlantic Bio Angels- APAriel Savannah Angel Partners
IAG Capital Partners
Charleston Angel Partners
Corza Medical- SSSSIP
Other known investors5 additional known investors
MedTech Innovator- APAriel Southeast Angel Partners
- KSKYTO Technology & Life Science
Sacha Levy
Tech Coast Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about New View Surgical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See New View Surgical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






